Bayer makes $62 billion cash offer for Monsanto

Bayer offers $62 billion for Monsanto
(Image credit: John MacDougall/AFP/Getty Images)

On Monday, Bayer AG formally unveiled a $62 billion offer for U.S. agribusiness giant Monsanto, offering a 37 percent premium over Monsanto's share price on May 9, the day before Bayer first disclosed its interest in the U.S. company. If completed, the all-cash deal would be the largest foreign acquisition by a German firm. "This transaction represents a compelling opportunity for Monsanto's shareholders," new Bayer CEO Werner Baumann argued in a conference call, providing investors "immediate and certain value." Bayer said it would finance the deal through selling shares and borrowing.

Bayer is better known as a pharmaceutical company, but it also makes pesticides, and buying Monsanto would makes its agricultural revenue roughly equal to its drug business, according to European investment bank Bryan Garner. Bayer focuses on agricultural chemicals, while Monsanto is best known for seeds. Not everyone approves of the proposed takeover, The Wall Street Journal notes. Some investors and analysts are worried that taking on so much debt would hurt Bayer's core pharmaceutical business, while others expressed concerns that buying Monsanto, the world's largest producer of genetically modified crops, would hurt Bayer's reputation, especially in anti-GMO Europe.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us